Yayınlar & Eserler

Yayın Ağı
Makaleler 32
Tümü (32)
SCI-E, SSCI, AHCI (26)
SCI-E, SSCI, AHCI, ESCI (29)
ESCI (2)
Scopus (32)
TRDizin (4)

1. Determinants of severity in immune checkpoint inhibitor–related pneumonitis: clinical, radiologic, and laboratory insights from real-life clinical data

Akkurt E. S., Duvenci Birben O., Deliktas Onur I., Dagli D., Ates O., YENİBERTİZ D.
BMC Cancer , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

2. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

Oruç A., Deliktaş Onur İ., Uyar G. C., ŞAHİN T. K., Tünbekici S., ARSLAN KAPUCİ A., et al.
Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

3. Dural-only metastases in breast cancer: clinical course, prognostic factors, and implications for central nervous system management

Önder T., Ateş Ö.
Memo - Magazine of European Medical Oncology , cilt.19, sa.3, ss.204-210, 2026 (ESCI, Scopus)

4. Phenotypic Age Acceleration Predicts Survival Outcomes in HR+/HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Cohort Study

Önder T., Ateş Ö.
Clinical Breast Cancer , cilt.26, sa.9, ss.53-61, 2026 (SCI-Expanded, Scopus)

5. Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2−metastatic breast cancer

Önder T., Ateş Ö.
Breast Cancer , cilt.33, sa.5, ss.1214-1226, 2026 (SCI-Expanded, Scopus)

6. Local Ablative Therapy in Breast Cancer Liver Metastases: Survival Outcomes and Prognostic Factors—A Single-Center Retrospective Study

Sertesen Çamöz E., Bayrak A., Karaçin C., Törenek Ş., Deliktaş Onur İ., Önder T., et al.
Journal of Clinical Medicine , cilt.15, sa.11, 2026 (SCI-Expanded, Scopus)

7. Prognostic Value of the Inflammatory Burden Index (IBI) in Metastatic Urothelial Carcinoma Prior to First-Line Therapy

Bilgetekin I., Demir N., Eraslan E., Akdagcik Z., Deliktas Onur I., Ates O., et al.
Medicina (Lithuania) , cilt.62, sa.6, 2026 (SCI-Expanded, Scopus)

8. Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study)

Onur İ. D., Özdemir P. A., Akdoğan O., Başkurt K., Kara M. I., Kalkan D. Ö., et al.
Supportive Care in Cancer , cilt.33, sa.12, 2025 (SCI-Expanded, Scopus)

9. Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective study

ŞAHİN T. K., EROĞLU İ., Dilli I., Sutcuoglu O., Chalabiyev E., GÜVEN D. C., et al.
Discover Oncology , cilt.16, sa.1, 2025 (SCI-Expanded, Scopus)

10. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study †

Deliktaş Onur İ., DOĞAN M., Öztürk M. A., ŞAHİN T. K., Kiracı M., Arslan A. M., et al.
Current Oncology , cilt.32, sa.11, 2025 (SCI-Expanded, Scopus) Creative Commons License

11. Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy

Yazgan S. C., Kayaş K., Arslan Ç., Kapar C., Öztekin Ş., Ceylan F., et al.
Oncologist , cilt.30, sa.9, 2025 (SCI-Expanded, Scopus)

12. Association of TILs and HER2-low status with pathological response in triple-negative breast cancer

Deliktaş Onur İ., Kurukafa D., Aǧyol Y., Firat H. G., Sertesen Çamöz E., Türkel A., et al.
Medicine (United States) , cilt.104, sa.33, 2025 (SCI-Expanded, Scopus)

13. Clinical Outcomes of Endocrine Therapy Plus CDK4/6 Inhibitors in Elderly Patients with HR+/HER2-Low Metastatic Breast Cancer

Yaşar S., İnci B. K., KUBİLAY TOLUNAY P., Aydemir E., Usta Ş., Topkaç A., et al.
Acta Haematologica Oncologica Turcica , cilt.58, sa.2, ss.93-98, 2025 (Scopus, TRDizin) Creative Commons License

14. Sinonasal Cancers: Single Center Experience

Camoz E. S., ATEŞ Ö., KILIÇ C., GÖKSEL F., ATASEVER AKKAŞ E., Onur I. D., et al.
Indian Journal of Otolaryngology and Head and Neck Surgery , cilt.77, sa.8, ss.2759-2765, 2025 (ESCI, Scopus)

15. Prognostic value of HER2 2 + expression in patients with TNBC receiving adjuvant capecitabine

Önder T., Cengiz M., Koçoğlu S. S., ATEŞ Ö., YAZICI O., İNANÇ M., et al.
Clinical and Translational Oncology , cilt.27, sa.7, ss.3121-3129, 2025 (SCI-Expanded, Scopus)

16. PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors

Önder T., Öner İ., Karaçin C., ATEŞ Ö.
International Journal of Clinical Oncology , cilt.30, sa.7, ss.1341-1354, 2025 (SCI-Expanded, Scopus)

17. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

TURAN N., ÇİL T., Artac M., Hacibekiroglu I., Sümbül A. T., Uncu D., et al.
Journal of Clinical Oncology , cilt.43, 2025 (SCI-Expanded, Scopus)

18. Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors

Önder T., Öner İ., Karaçin C., ATEŞ Ö.
Japanese Journal of Clinical Oncology , cilt.55, sa.6, ss.578-587, 2025 (SCI-Expanded, Scopus)

19. Evaluation of the Effect of Radiotherapy Timing on Toxicity in HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine During the Adjuvant Period

Onur İ. D., KAVGACI G., Kuzu Ö. F., Başoğlu T., ATEŞ Ö., Karaçin C.
Acta Haematologica Oncologica Turcica , cilt.58, sa.1, ss.12-15, 2025 (Scopus, TRDizin) Creative Commons License

20. Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

ŞAHİN T. K., Atalah F., Koylu B., Oruc A., Acarbay A., Karakok A., et al.
Frontiers in Immunology , cilt.16, 2025 (SCI-Expanded, Scopus) Creative Commons License

21. Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Önder T., ATEŞ Ö., Öner İ., Karaçin C.
Clinical Breast Cancer , cilt.24, sa.6, ss.519-526, 2024 (SCI-Expanded, Scopus)

22. Predicting survival after brain metastases in patients with bladder cancer

Önder T., Karaçin C., Kekilli E., GÖKSEL F., Sertesen E., Onur İ. D., et al.
Journal of Clinical Neuroscience , cilt.125, ss.146-151, 2024 (SCI-Expanded, Scopus)

23. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., ERSOY M., et al.
Future Oncology , cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded, Scopus)

24. Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients

ERDEM H. B., Alay M. T., Özdemir Z., Çevik E., ATEŞ Ö., Karaçin C., et al.
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis , cilt.828, 2024 (Scopus)

25. Presentation of Metastatic Cholangiocellular Cancer with Orbital Metastasis Metastatik Kolanjıoselüler Kanserin Orbital Metastaz ile Prezentasyonu

Onur İ. D., ATEŞ Ö., ÜNAL Ö.
Acta Haematologica Oncologica Turcica , cilt.57, sa.1, ss.35-38, 2024 (Scopus, TRDizin) Creative Commons License

26. Clinicopathological features of non-carcinoid malignant epithelial appendix tumors and risk factors for recurrence, single-center experience

ATEŞ Ö., AKSEL B., KARADAĞ İ., KARAKAYA S., Sunar V., Oksuzoglu O. B.
Indian Journal of Cancer , cilt.61, sa.2, ss.305-311, 2024 (SCI-Expanded, Scopus)

27. Efficacy and Safety of Combined Chemotherapy Regimens with Bevacizumab in Platinum-sensitive Ovarian Cancers

Tay F., Buyukkor M., ATEŞ Ö.
Journal of the College of Physicians and Surgeons Pakistan , cilt.33, sa.9, ss.1006-1011, 2023 (SCI-Expanded, Scopus) Creative Commons License

28. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling

Özdemir Z., Çevik E., Öksüzoğlu Ö. B. Ç., DOĞAN M., ATEŞ Ö., Esin E., et al.
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis , cilt.827, 2023 (SCI-Expanded, Scopus)

29. Non-Invasive Liver Fibrosis Scores can Predict Hepatic Metastasis in Colorectal Cancers

KARAKAYA S., KARADAĞ İ., ATEŞ Ö.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.32, sa.2, ss.102-108, 2022 (SCI-Expanded, Scopus, TRDizin)

30. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data

ATEŞ Ö., Oksuzoglu O. B., AKTAŞ B. Y., KARADAĞ İ., Esen S., KARAKAYA S., et al.
Journal of B.U.ON. , cilt.26, sa.4, ss.1398-1404, 2021 (SCI-Expanded, Scopus)

31. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases

ATEŞ Ö., YALÇIN Ş.
Indian Journal of Cancer , cilt.56, sa.2, ss.176-179, 2019 (SCI-Expanded, Scopus)

32. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., ATEŞ Ö., et al.
Journal of B.U.ON. , cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded, Scopus)
Metrikler

Yayın

32

Yayın (WoS)

29

Yayın (Scopus)

32

H-İndeks (WoS)

4

Atıf (Scopus)

48

H-İndeks (Scopus)

5

Tez Danışmanlığı

4

Açık Erişim

11